Pepscan Therapeutics establishes a Research Collaboration with Tibotec Pharmaceuticals
"Pepscan has recently realigned its R&D program to focus on the application of its proprietary CLIPS protein mimicry technology for the generation of novel therapeutic peptides and immunogens", said Wim Mol, CEO of Pepscan. "We are very pleased that Tibotec has decided to enter into a collaboration agreement with Pepscan that will utilize the CLIPS technology. We are convinced that our strong technology and expertise can yield improved peptides with superior activity and proteolytic stability, all this with a significantly shorter peptide." “We consider this agreement a further expression of our leadership position in the field of protein mimicry”, he added.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.